|
05 April 2002
Auckland, 5th April 2002 – Genesis Research and Development Corporation Ltd [NZSE / ASX: GEN] advises that it has applied to the Australian Stock Exchange to transfer its current ‘Foreign Exempt’ listing to ‘Full Listing’ status, in response to the ASX intended amendments to the Listing Rule provisions relating to Foreign Exempt entities. Genesis will continue to maintain its home listing on the New Zealand Stock Exchange. About Genesis Founded in 1994, Genesis is a New Zealand based biotechnology company committed to the development of innovative products in health and plant biotechnology from its broad genomic platform. Genesis partners with industry leaders to develop products which have global market potential through the mining of its extensive microbe, plant and mammalian EST databases. The Health Sciences Division focuses on signalling pathways and the immune system and has an extensive patent portfolio. It has three programmes in human clinical development utilising PVAC™ and AVAC™ for the treatment of psoriasis, atopic dermatitis (eczema) and asthma. Additional pre-clinical programmes are developing YB-1, FGFR5, MED-1 and Epigen for cancer and other indications. The patented BioStore solutions for storage of tissues and living cells are also in pre-clinical development. Collaborations are maintained with Immunex Corporation (NASDAQ: IMNX), Corixa Corporation (NASDAQ: CRXA), SR Pharma (LSE: SPA), and Jurox Pty Ltd. The Plant Sciences division is focusing on key cell signalling genes – novel hormones and transcription factors - to control commercial traits including wood fibre quality in trees, nutritional content of forage grasses, flowering control, salt and cold tolerance and superior growth rates. It has developed comprehensive plant EST databases including the world’s largest EST database for commercial forestry species. It has research collaborations with ArborGen LLC, Wrightson (NZSE: WRI), HortResearch, AgResearch and Landcare. Genesis is also undertaking significant unpartnered research programmes in novel plant hormones. A number of patents are held including 12 steps in the production of lignin. For more information, please visit www.genesis.co.nz Media contacts: Dr James D Watson, Chief Executive, Genesis Research and Development Corporation Limited, +64 9 373 5600 Allan Botica, Botica Conroy and Associates, +64 9 303 3862, +64 21 400 500, allanb@bca.co.nz |